Datopotamab deruxtecan
Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2) -directed antibody-drug conjugate (ADC) . Datopotamab deruxtecan has a potent antitumor activity[1].
Product Specifications
CAS Number
[2238831-60-0]
Product Name Alternative
DS-1062; Dato-DXd
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Topoisomerase; TROP2
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/datopotamab-deruxtecan.html
Purity
99.54
Solubility
10 mM in DMSO
Smiles
[Datopotamabderuxtecan]
Molecular Weight
149000 (average)
References & Citations
[1]Daisuke Okajima, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Aug 19.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Launched
Isoform
Topo I
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items